Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D213/79—Acids; Esters

Definitions

• composition comprising, as an essential active hypotensive ingredient thereof, a pharmaceutically effective amount of a compound having the general structural formula:
• X represents a member of the group consisting of lower alkyl, lower alkenyl, lower alkoxy, phenyl and X substituted phenyl wherein X is a member of the group consisting of lower alkoxy, halogen, trifiuoromethyl and hydroxy, X being located at the 3-, 4- or 5-positions
• R represents a member of the group consisting of OH, O-lower alkyl, and NR R wherein R is a member of the group consisting of hydrogen, methyl and ethyl, and R is a member of the group consisting of hydrogen, methyl, ethyl and, when R is hydrogen, R is also hydroxy and cyclopropyl.
• lower alkyl and lower alkoxy include the straight, cyclized and branched chain radicals having from 1 to 8 carbon atoms and, for purposes of illustration, embrace such radicals as methyl, ethyl, n-butyl, isopropyl, cyclopropyl, cyclohexyl, cyclohexylmethyl, cyclopentyl, methoxy, ethoxy, propoxy, cyclopropoxy, n-butoxy, and the like,
• lower alkenyl is limited to those straight and cyclized unsaturated radicals having 3 to 6 carbon atoms and, for
• esters of Formula I i.e., when R represents O-lower alkyl, are methyl and ethyl and such other esters derived from alcohols having up to six carbon atoms.
• the preferred halogen substituents are chloro and bromo.
• the X-substituted picolinic acids and the esters and amides of Formula I are compounds which are well known or may be readily prepared by methods analogous to those fully described in the art.
• S-n-butyl-picolinamide mix 25 g. of S-n-butylpicolinic acid and 25 ml. of thionyl chloride; after all of the acid is dissolved, concentrate (in vacuo) the mixture and take up the mixture in 500 ml.
• hypotensive agents of this invention can be administered as such, or can be administered in the form of a composition comprising the active ingredient and any of the commonly used pharmaceutical carriers.
• These carriers must be compatible with the active ingredient, and can be either solid or liquid, therapeutically active or insert. By using such carriers, one can make these compositions in the form of tablets, capsules, powders, oral suspensions, or syrups.
• the compositions can also be made in theform of sterile solutions which are suitable for injection.,The compositions will contain from 1% to by weight of active compound, and from 5% to 99% by weight of a suitable pharmaceutical carrier. These ranges, however, are not critical and can be varied as desired according to the circumstances.
• a sterile solution suitable for injection is prepared by admixing from 0.5 to 5 parts by Weight of the active ingredient, preferably in the form of its alkali metal salt, and from 95 to 99.5 parts by weight of Water or isotonic saline solution at a temperature and for time sufficient to dissolve the active ingredient. This solution is then sterilized by filtration or by the application of heat. The solution is preferably sterilized in an autoclave at a steam pressure of 15 pounds per square inch for from 5 to 15 minutes.
• a preferred solution for injection also contains preservatives such as a mixture of methyland propylparaben benzoic acid, or other nontoxic antimicrobial agents.
• injectable solutions can be prepared with a high concentration of active ingredient. The solution is then diluted to a desired concentration before it is used.
• the compounds of Formula I can also be administered in the form of hard or soft gelatin capsules. These capsules are filled with the proper amount of active ingredient and a solid filler, such as starch, gelatin, lactose, talc, stearic acid, or magnesium stearate. Such a capsule can contain from 50 to 250 milligrams of active material, thus providing a minimum dose of active ingredient in a form convenient for oral administration.
• a solid filler such as starch, gelatin, lactose, talc, stearic acid, or magnesium stearate.
• the compounds of Formula I when mixed with a suitable carrier, can also be formulated as tablets.
• Such carriers must be compatible with the active ingredient and can be the carriers mentioned for use with capsules, or can be such binders or fillers as cornstarch, acacia, gelatin, or cellulosic materials.
• any of the tableting materials conventionally used in pharmaceutical practice can be employed if there is no incompatibility with the active ingredient.
• the tablets are made by admixing the active ingredient, a suitable filler, a lubricant or mold-release agent, and a binder, and compressing the mixture in a conventional tableting machine into tablets of a preselected size.
• each tablet will contain from 50 to 250 milligrams of active ingredient.
• the tablets can be scored so that they are easily broken.
• the tablets can be coated with tablet-coating materials in order to make them more attractive and palatable. They can also have enteric coatings so that they will release their ingredients slowly and over a longer period.
• the compounds of Formula I can also be formulated and administered as suspensions or syrups.
• the antihypertensive compound is usually present in such suspensions and syrups in amounts of from 1% to 5% by weight, however, lower or higher concentrations can be used.
• the pharmaceutical carrier in such suspensions or syrups can be an aqueous vehicle such as an aromatic water, a syrup, or a pharmaceutical mucilage.
• Suitable aromatic waters include the following: Anise Water, N.F. (IX); Bitter Almond Water, N.F. (VIII); Camphor Water, N.F.; Cinnamon Water, U.S.P.; Fennel Water, N.F.; Peppermint Water, U.S.P.; Spearmint Water, N.F. (IX); Wintergreen Water, N.F. (IX).
• Suitable syrups include the following: Syrup (Simple Syrup), U.S.P.; Acacia Syrup, U.S.P.; Aromatic Eriodictyon Syrup, N.F.; Aromatic Rhubarb Syrup, N.F. (IX); Cacao Syrup, U.S.P.; Cherry Syrup, U.S.P.; Cinnamon Syrup, N.F. (IX); Citric Acid Syrup, U.S.P.; Compound Sarsparilla Syrup, N.F.; Compound White Pine Syrup, N.F.; Ginger Syrup, N.F.
• Suitable pharmaceutical mucilages include the following: Acacia (Gum Arabic), U.S.P.; Acacia Mucilage, U.S.P.; Tragacanth, U.S.P.; Tragacanth Mucilage, N.F.
• the pharmaceutical carrier in the suspensions or syrups can also be a hydroalcoholic vehicle, such as an elixir.
• Suitable elixirs include the following: Aromatic Elixir, U.S.P.; Red Aromatic Elixir, N.F.; Glycyrrhiza Elixir, N.F.; Iso-Alcoholic Elixir (Iso-Elixir), N.F. Coloring agents, tinctures, spirits and other adjuvants can be admixed witth the composition if desired.
• TABLET FORMULATION Mix the S-n-butylpicolinamide, the lactose and the dicalcium phosphate. Dissolve the polyethylene glycol 1500 and the polyvinylpyrrolidone in approximately 20 ml. of water. Granulate the powder blend with the Water solution, adding additional water if necessary, to produce a damp mass. Pass the wet granulation through a 12 mesh screen; spread on trays and air dry at 35 C. Blend the dry granules with the starch and the magnesium stearate. Compress into 500 mg. tablets.
• INJECTION FORMULATION Formula Grams per 1000 ampuls 5-n-butyl N,N dimethylpicolinamide 110.0 Water for injection, q.s. 1100.0 ml.
• the present invention resides in the concept of antihypertensive compositions wherein the essential active ingredient is 5-X-picolinamide or the N-methyl or N,N-dimethylamido derivatives thereof wherein X is a member selected from the group consisting of lower alkyl or lower alkoxy groups having from 1 to 5 carbon atoms. It is contemplated that dosage units of such compositions will be administered daily, either as tablets, capsules, elixirs, or the like, or by injection, in order to achieve an anti-hypertensive response.
• X-substituted picolinic acids, and esters and amides thereof may be formulated into pharmaceutically acceptable compositions useful for lowering high blood pressure:
• S-n-butylpicolinic acid 5-t-butylpico1inic acid; 5-propylpicolinic acid; 5-cyclopropylpicolinic acid; S-ethylpicolinic acid; S-butenylpicolinic acid; 5-cyclopentenylpicolinic acid; S-methoxypicolinic acid; 5-ethoxypicolinic acid; 5-propoxypicolinic acid; 5-hexylpicolinic acid; 5-cyclopentylpicolinic acid; 5-isopropoxypicolinic acid; S-pentylpicolinic.
• the second phase is a post-metacorticoid hypertension which is self-sustaining for as much as a year.
• This hypertension resembles human essential hypertension in several respects. Pathological changes observed in kidneys and heart are similar to those seen at post-mortem in untreated human essential hypertension. Furthermore, drugs which affect human hypertension also are similarly active in this rat model.
• the hypertensive rat is minimally restrained in a plastic chamber and sphygmomanometer cuff is placed at the base of the tail. A sensitive condenser-microphone pickup is then taped to the tail. This device permits the electronic sensing and recording of the arterial pulse exactly as in classical s-phygmomanometry.
• the drugs were administered orally. Readings of systolic pressure were taken on an oscilloscope using an aneroid' pressure sensor hourly after oral administration.
• the method of lowering high blood pressure in warm blooded animals is effected by administering a therapeutically effective quantity of an X-substituted picolinic acid, ester or amide (as defined for Formula I above).
• the therapeutically effective quantity of a compound of Formula I may readily be ascertained by standard and well-known techniques in the art.
• One such laboratory technique is the Desoxycorticosterone Acetate Hypertension Test in the rat (DOCA-Hypertension- Rat) described as follows:
• Rats will become hypertensive if a 25 mg. pellet of desoxycorticosterone acetate is subcutaneously implanted at the same time as 1 percent NaCl is substituted for normal drinking water. This hypertension passes through two phases. The first is that induced solely by the salt retaining effect of the-mineralocorticoid and persists until the Accordingly, from the foregoing test procedures as well as by other standard laboratory techniques as well as by comparison with well-known hypotensive agents, the therapeutically effective dosage range for lowering high blood pressure in warm-blooded animals is readily determined. From these tests a therapeutically effective dosage range for the compounds of this invention is 15-250 mg./kg. of body weight.
• a therapeutically effective dosage will be administered about three times daily
• the actual total daily dosage will depend upon the degree of severity of the hypertension, its cause and other health factors of the hypertensive warm blooded animal.
• the attending diag nostician will determine the dosage frequency and degree of lowering the high blood pressure.
• u-adrenergic blocking compounds phentolamine or dibenzyline
• amine depleters reserpine or syrosingopine
• false transmitter-depleter or-methyl dopa
• post-ganglionic adrenergic neurone blockers all decrease arterial pressure by modulating some component(s) of the adrenergic nervous system.
• the anti-hypertensive therapy of these compounds could involve enzyme inhibition of neurotransmitter synthesis. Since norepinephrine is the sympathetic neurohumoral transmitter which plays a key role in the maintenance of blood pressure, inhibition of its synthesis should yield an effective anti-hypertensive agent. Suppression of norepinephrine synthesis from its immediate precursor, dopamine, can be achieved by an adequate inhibition of the I enzyme, dopamine fi-hydroxylase. In their action in warm blooded animals it is found that the compounds of this invention are inhibitors of dopamine p-hydroxylase.
• the toxic dosage levels (LD of the compounds of this invention is significantly greater than the minimal effective dosage range necessary to achieve a hypotensive effect.
• Specific compounds of this invention which are of particular interest for their anti-hypertensive effect in warm-blooded animals are: S-n-butylpicolinamide; S-n-butylpicolinic acid; 5n-butyl-N,N-dimethylpicolinamide; S-cyclopentylpicolinic acid; 5cyclopentylpicolinamide; S-cyclohexylpicolinic acid; S-phenylpicolinic acid; 3-n-butylpicolinamide; 3-n-butylpicolinic acid and 3-n-butyl-N,N-dimethylpicolinamide.
• the compounds of this invention may also be combined with known diuretics, particularly the thiazide diuretics, and with known hypotensive agents so as to achieve enhanced hypotensive effects.
• a method of lowering high blood pressure comprising administering to a warm-blooded animal having high blood pressure, a therapeutically effective quantity of a compound of the formula I E H R wherein X represents a member of the group consisting of lower alkyl, lower alkenyl of 3 to 6 carbon atoms, lower alkoxy, phenyl and X substituted phenyl wherein X is a member of the group consisting of lower alkoxy, chlorine, bromine, trifluoromethyl and hydroxy, R represents a member of the group consisting of OH, O-lower alkyl, and NR R wherein R is a member of the group consisting of hydrogen, methyl and ethyl, and R is a member of the group consisting of hydrogen, methyl, ethyl and, when R is hydrogen, R is also hydroxy and cyclopropyl.
• X represents a member of the group consisting of lower alkyl, lower alkenyl of 3 to 6 carbon atoms, lower al
• X represents a member of the group consisting of lower alkyl, lower alkenyl of 3 to 6 carbon atoms, lower alkoxy, phenyl and X substituted phenyl wherein X is a member of the group consisting of lower al-koxy, chlorine, bromine, trifiuoromethyl and hydroxy
• R represents a member of the group consisting of OH, -O-lower alkyl
• NR R wherein R is a member of the group consisting of hydrogen, methyl and ethyl, and R is a member of the group consisting of hydrogen, methyl, ethyl and, when R is hydrogen, R isalso hydroxy and cyclopropyl.
• X represents a member of the group consisting of lower alkyl, lower alkenyl of 3 to 6 carbon atoms, lower alkoxy, phenyl and X substituted phenyl wherein X, is a member of the group consisting of lower alkoxy, chlorine, bromine, trifluoromethyl and hydroxy
• R represents a member of the group consisting of OH, O-lower alkyl
• NR R wherein R is a member of the group consisting of hydrogen, methyl and ethyl, and R is a member of the group consisting of hydrogen, methyl, ethyl and, when R is hydrogen, R is also hydroxy and cyclopropyl.
• X represents a member of the group consisting of lower alkyl, lower alkenyl of 3 to 6 carbon atoms, lower alkoxy, phenyl and X substituted phenyl wherein X is a member of the group consisting of lower alkoxy, chlorine, bromine, trifluoromethyl and hydroxy.
• X represents a member of the group consisting of lower alkyl, lower alkenyl of 3 to 6 carbon atoms, lower alkoxy, phenyl and X substituted phenyl wherein X is a member of the group consisting of lower alkoxy, chlorine, bromine, trifluoromethyl and hydroxy, R is a member of the group consisting of hydrogen, methyl and ethyl, and R is a member of the group consisting of hydrogen, methyl, ethyl and, when R is hydrogen, R is also hydroxy and cyclopropyl.
• X represents a member of the group consisting of lower alkyl, lower alkenyl of 3 to 6 carbon atoms, lower alkoxy, phenyl and X substituted phenyl wherein X is a member of the group consisting of lower alkoxy, chlorine, bromine, trifluorornethyl and hydroxy.
• X represents a member of the group consisting of lower alkyl, lower alkenyl of 3 to 6 carbon atoms, lower alkoxy, phenyl and X substituted phenyl wherein X is a member of the group consisting of lower alkoxy, chlorine, bromine, trifiuoromethyl and hydroxy, R is a member of the group consisting of hydrogen, methyl and ethyl, and R is a member of the group consisting of hydrogen, methyl, ethyl and, when R, is hydrogen, R is also hydroxy and cyclopropyl.
• R is a member of the group consisting of hydrogen, methyl and ethyl
• R is a member of the group consisting of hydrogen, methyl, ethyl and, when R is hydrogen, R is also hydroxy and cyclopropyl.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Pyridine Compounds (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=24805016

Family Applications (1)

Country Status (6)

Cited By (11)

Citations (2)

• 1968
  • 1968-01-17 US US698385A patent/US3519717A/en not_active Expired - Lifetime
  • 1968-03-28 NL NL686804364A patent/NL147633B/nl not_active IP Right Cessation
  • 1968-04-06 DE DE1767163A patent/DE1767163C3/de not_active Expired
  • 1968-04-08 IL IL29778A patent/IL29778A/xx unknown
  • 1968-09-23 FR FR167134A patent/FR7929M/fr not_active Expired
  • 1968-10-08 BE BE722002D patent/BE722002A/xx unknown

Patent Citations (2)

Also Published As

Similar Documents